Impact of R0/R1 Margin Status on Overall Survival in Node-Positive Resected Pancreatic Ductal Adenocarcinoma: Meta-Analysis.

Ann Surg OncolJul 8, 2026 (epub)
Clinical ResearchOncology (Medical)General SurgeryOpen access

A M Bonomi, S Granieri, R M Montorsi et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the impact of R0 versus R1 margin status on overall survival in 19,206 patients with node-positive resected pancreatic ductal adenocarcinoma (PDAC). The study found that R1 resection was associated with worse overall survival (HR: 1.38; 95% CI: 1.21-1.59), reinforcing the importance of achieving R0 resection even in node-positive cases.

Key findings

  • R1 resection was associated with worse overall survival (HR: 1.38; 95% CI: 1.21-1.59).
  • The overall R0N+ rate was 61.1%, varying significantly by the application of the Royal College of Pathology protocol.
  • In RCP-compliant cases, R1N+ resections also showed worse overall survival (HR: 1.25; 95% CI: 1.10-1.42).

Why it matters

The findings highlight the continued relevance of achieving R0 resection in node-positive PDAC, as R1 status is linked to poorer survival outcomes. This underscores the need for careful surgical planning and margin assessment.

Source

PubMed · PMID 42418088Free full text on PubMed Central

Published in Ann Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.